FWM
CLVS

Focused Wealth Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Focused Wealth Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,000
Closed -$45K – 737
2018
Q2 		$45K Hold
1,000
– – 0.02% 287
2018
Q1 		$53K Sell
1,000
-15
-1% -$875 0.02% 294
2017
Q4 		$69K Sell
1,015
-85
-8% -$5.94K 0.02% 265
2017
Q3 		$91K Sell
1,100
-15
-1% -$1.19K 0.03% 169
2017
Q2 		$104K Sell
1,115
-1,100
-50% -$67.3K 0.04% 219
2017
Q1 		$141K Hold
2,215
– – 0.06% 185
2016
Q4 		$98K Sell
2,215
-2,650
-54% -$93.3K 0.04% 216
2016
Q3 		$175K Hold
4,865
– – 0.08% 155
2016
Q2 		$67K Buy
4,865
+2,189
+82% +$32K 0.03% 238
2016
Q1 		$51K Buy
2,676
+140
+6% +$2.96K 0.03% 192
2015
Q4 		$89K Buy
2,536
+1,293
+104% +$83.4K 0.05% 160
2015
Q3 		$114K Buy
1,243
+93
+8% +$8.05K 0.07% 132
2015
Q2 		$101K Buy
+1,150
New +$98.4K 0.06% 138

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Focused Wealth Management's CLVS Position: Q3 2018 in Review

Focused Wealth Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 1,000 shares — an estimated $45K sold.

Focused Wealth Management first reported a position in CLVS in Q2 2015 and held it in 13 quarters. The position peaked at $175K in Q3 2016. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

  • Focused Wealth Management reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
  • Focused Wealth Management sold 1,000 Clovis Oncology, Inc. shares in Q3 2018, an estimated $45K.
  • Focused Wealth Management first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 13 quarters.
  • Focused Wealth Management's Clovis Oncology, Inc. position peaked at $175K in Q3 2016.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Focused Wealth Management's 13F filing for Q3 2018, filed 13 Nov 2018.